California office of berman tabacco launches investigation into potential securities claims against fibrogen inc. (fgen) in connection with roxadustat "clarification"

San francisco, california--(newsfile corp. - april 7, 2021) - berman tabacco, a national law firm representing investors, is investigating potential securities law claims against fibrogen inc. ("fibrogen" or the "company") (nasdaq: fgen). fibrogen is a san francisco-based biopharmaceutical company developing roxadustat, a treatment of anemia in chronic kidney disease ("ckd").on november 8, 2019, the company issued a press release announcing, "positive phase 3 pooled roxadustat safety and efficacy results for treatment of anemia in...
FGEN Ratings Summary
FGEN Quant Ranking